News | October 28, 2022
Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
AB PMJAY has been successful in providing quality health services to the beneficiaries who come from weak financial backgrounds
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Subscribe To Our Newsletter & Stay Updated
